Breaking News, Collaborations & Alliances

Quell Therapeutics, eXmoor Pharma Partner for CAR-Treg Cell Therapy Manufacturing

Multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies.

Author Image

By: Charlie Sternberg

Associate Editor

Quell Therapeutics Ltd, a leader in engineered T-regulatory (Treg) cell therapies, and eXmoor pharma, a cell and gene therapy (CGT) manufacturing partner, have announced a strategic partnership to manufacture Quell’s pipeline of autologous engineered CAR-Treg cell therapies for autoimmune diseases.   Quell’s innovative Foxp3 Phenotype Lock technology and multi-modular platform enable the development of highly targeted, potent, and persistent Treg cell therapies. The company has ext...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters